Pharma channel feed

Bio­gen nabs FDA ap­proval for its biosim­i­lar of arthri­tis and Covid-19 drug Actem­ra

Last year
FDA+

Fed­er­al judge de­nies Cham­ber of Com­merce's ef­fort to block IRA's Medicare drug price ne­go­ti­a­tion pro­vi­sions

Last year
FDA+

All phar­ma com­pa­nies in the first round of Medicare price ne­go­ti­a­tions agree to par­tic­i­pate

Last year

In­fin­i­ty Phar­ma­ceu­ti­cals files for bank­rupt­cy af­ter lay­offs, scrapped merg­er with MEI Phar­ma

Last year

Sen. Bill Cas­sidy calls on hos­pi­tals to pro­vide more in­for­ma­tion on how they use 340B funds

Last year

MEI Phar­ma push­es back on ac­tivist in­vestors af­ter failed merg­er with In­fin­i­ty

Last year

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

Last year
FDA+

PBM re­forms: Sen­ate Fi­nance Com­mit­tee lead­ers in­tro­duce an­oth­er bi­par­ti­san bill

Last year

CDER tweaks Ozem­pic’s post-mar­ket­ing la­bel to in­clude risk for GI dis­or­der

Last year

Mer­ck to par­tic­i­pate in Medicare ne­go­ti­a­tions process 'un­der protest,' fol­low­ing at least three oth­ers

Last year

GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

Last year

Bris­tol My­ers teams with so­cial me­dia in­flu­encer and singer to spark rare heart con­di­tion aware­ness

Last year
Marketing

Boehringer agrees to com­ply with CM­S' price ne­go­ti­a­tions over block­buster Jar­diance

Last year

FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

Last year
AI
FDA+

Cost-ef­fec­tive­ness of Mer­ck’s po­ten­tial hy­per­ten­sion drug will hinge on long-term da­ta, ICER says

Last year

How Tik­Tok’s al­go­rithm and au­di­ences are fi­nal­ly con­vinc­ing Big Phar­ma to join

Last year
Marketing

Mar­ket­ingRx roundup: Phar­ma in­dus­try rep drops in Gallup poll; Pfiz­er web­site re­veals not-yet-ap­proved drug name

Last year
Marketing

Bris­tol My­ers joins As­traZeneca in agree­ing to drug price ne­go­ti­a­tion terms ahead of first dead­line

Last year
Law

No­vo Nordisk forms car­diometa­bol­ic drug dis­cov­ery ac­cel­er­a­tor to get to re­search faster

Last year

Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

Last year
Deals

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Last year
Deals
R&D

CDC ad­vi­sors rec­om­mend Pfiz­er's ma­ter­nal RSV vac­cine in 11-1 vote

Last year
FDA+

Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

Last year
Marketing

Boehringer In­gel­heim, Eli Lil­ly clinch new FDA ap­proval for block­buster Jar­diance to treat chron­ic kid­ney dis­ease

Last year
FDA+
First page Previous page 9899100101102103104 Next page Last page
A service from the Financial Times